Symbols / PLRZ $11.68 +1.57% Polyrizon Ltd.
PLRZ Chart
About
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 18.95M |
| Enterprise Value | 1.59M | Income | -3.33M | Sales | — |
| Book/sh | 18.74 | Cash/sh | 10.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.62 | P/C | — |
| EV/EBITDA | -0.27 | EV/Sales | — | Quick Ratio | 25.94 |
| Current Ratio | 29.03 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -4.82 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -28.95% |
| ROE | -25.38% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.62M |
| Shs Float | 1.05M | Short Float | 3.72% | Short Ratio | 1.08 |
| Short Interest | — | 52W High | 2235.00 | 52W Low | 2.88 |
| Beta | — | Avg Volume | 83.34K | Volume | 46.18K |
| Target Price | — | Recom | None | Prev Close | $11.50 |
| Price | $11.68 | Change | 1.57% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$11.68
Latest analyst target
3. DCF / Fair value
$-51.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.68
Low
—
High
—
Mean
—
- Director at Polyrizon (PLRZ) sells 100 shares, retains 4,069 - Stock Titan ue, 31 Mar 2026 20
- Polyrizon (PLRZ) CTO trims stake with 2,917-share open-market sale - Stock Titan ue, 31 Mar 2026 20
- We're Keeping An Eye On Polyrizon's (NASDAQ:PLRZ) Cash Burn Rate - simplywall.st Sat, 28 Mar 2026 12
- PLRZ Stock Price and Chart — NASDAQ:PLRZ - TradingView hu, 04 Dec 2025 08
- We're Keeping An Eye On Polyrizon's (NASDAQ:PLRZ) Cash Burn Rate - Sahm Sat, 28 Mar 2026 07
- Polyrizon (PLRZ) CEO sells 3,900 shares, holding 32,012 afterward - Stock Titan ue, 31 Mar 2026 20
- Polyrizon pushes allergy and viral nasal blockers toward U.S. trials - Stock Titan hu, 26 Mar 2026 13
- Polyrizon posts 2025 Form 20-F, offers free copies to holders - Stock Titan Wed, 25 Mar 2026 21
- Polyrizon (PLRZ) updates 20-F, outlines $464,000 cyber fraud response - Stock Titan Fri, 27 Mar 2026 13
- Polyrizon (PLRZ) Chief Science Officer reports share and option holdings - Stock Titan Wed, 18 Mar 2026 07
- Polyrizon makes GMP batch for planned U.S. nasal allergy, virus trial - Stock Titan ue, 10 Mar 2026 07
- Nasal allergy startup Polyrizon readies human trials with safety tests - Stock Titan ue, 17 Mar 2026 07
- Why a nasal drug developer wants a stake in an Israeli eVTOL drone maker - Stock Titan ue, 24 Mar 2026 12
- Adler Oz discloses Polyrizon (PLRZ) restricted share holdings and vesting - Stock Titan Wed, 18 Mar 2026 07
- Polyrizon (PLRZ) CEO Tomer Izraeli details initial share and option holdings - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
5.79
+344.32%
|
1.30
+105.04%
|
0.64
-29.05%
|
0.90
|
| Research And Development |
|
2.13
+299.44%
|
0.53
+60.84%
|
0.33
-4.32%
|
0.35
|
| Selling General And Administration |
|
3.65
+375.52%
|
0.77
+153.47%
|
0.30
-44.71%
|
0.55
|
| Selling And Marketing Expense |
|
—
|
0.00
|
0.00
-100.00%
|
0.01
|
| General And Administrative Expense |
|
3.65
+375.52%
|
0.77
+153.47%
|
0.30
-43.15%
|
0.53
|
| Salaries And Wages |
|
1.13
+596.30%
|
0.16
-3.57%
|
0.17
-11.58%
|
0.19
|
| Other Gand A |
|
2.52
+316.50%
|
0.61
+348.89%
|
0.14
-60.64%
|
0.34
|
| Total Expenses |
|
5.79
+344.32%
|
1.30
+105.04%
|
0.64
-29.05%
|
0.90
|
| Operating Income |
|
-5.79
-344.32%
|
-1.30
-105.04%
|
-0.64
+29.05%
|
-0.90
|
| Total Operating Income As Reported |
|
-6.25
-379.95%
|
-1.30
-105.04%
|
-0.64
+29.05%
|
-0.90
|
| EBITDA |
|
-5.44
-359.71%
|
-1.18
-87.64%
|
-0.63
+29.10%
|
-0.89
|
| Normalized EBITDA |
|
-10.67
-1000.72%
|
-0.97
-8.15%
|
-0.90
+8.76%
|
-0.98
|
| Reconciled Depreciation |
|
0.34
+189.83%
|
0.12
+2850.00%
|
0.00
-20.00%
|
0.01
|
| EBIT |
|
-5.79
-344.32%
|
-1.30
-105.04%
|
-0.64
+29.05%
|
-0.90
|
| Total Unusual Items |
|
5.22
+2529.30%
|
-0.21
-181.13%
|
0.27
+188.04%
|
0.09
|
| Total Unusual Items Excluding Goodwill |
|
5.22
+2529.30%
|
-0.21
-181.13%
|
0.27
+188.04%
|
0.09
|
| Special Income Charges |
|
-0.46
|
—
|
—
|
—
|
| Other Special Charges |
|
0.46
|
—
|
—
|
—
|
| Net Income |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Pretax Income |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Net Non Operating Interest Income Expense |
|
-2.77
-9803.57%
|
-0.03
+87.83%
|
-0.23
-1058.33%
|
0.02
|
| Net Interest Income |
|
-2.77
-9803.57%
|
-0.03
+87.83%
|
-0.23
-1058.33%
|
0.02
|
| Interest Income Non Operating |
|
0.37
|
0.00
|
0.00
|
—
|
| Interest Income |
|
0.37
|
0.00
|
0.00
|
—
|
| Other Income Expense |
|
5.22
+2529.30%
|
-0.21
-181.13%
|
0.27
+188.04%
|
0.09
|
| Gain On Sale Of Security |
|
5.69
+2745.12%
|
-0.21
-181.13%
|
0.27
+188.04%
|
0.09
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Net Income From Continuing Operation Net Minority Interest |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Net Income From Continuing And Discontinued Operation |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Net Income Continuous Operations |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Normalized Income |
|
-8.56
-543.46%
|
-1.33
-53.76%
|
-0.86
+0.69%
|
-0.87
|
| Net Income Common Stockholders |
|
-3.33
-107.79%
|
-1.60
-139.91%
|
-0.67
+18.71%
|
-0.82
|
| Diluted EPS |
|
—
|
-805.20
-236.52%
|
-239.27
+18.71%
|
-294.35
|
| Basic EPS |
|
—
|
-805.20
-236.52%
|
-239.27
+18.71%
|
-294.35
|
| Basic Average Shares |
|
—
|
0.00
-28.68%
|
0.00
+0.00%
|
0.00
|
| Diluted Average Shares |
|
—
|
0.00
-28.68%
|
0.00
+0.00%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-3.33
-107.79%
|
-1.60
-139.91%
|
-0.67
+18.71%
|
-0.82
|
| Preferred Stock Dividends |
|
—
|
0.06
-13.04%
|
0.07
+56.82%
|
0.04
|
| Total Other Finance Cost |
|
3.14
+11125.00%
|
0.03
-87.83%
|
0.23
+1058.33%
|
-0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
21.44
+286.46%
|
5.55
+892.31%
|
0.56
+2.38%
|
0.55
|
| Current Assets |
|
12.86
+384.73%
|
2.65
+4812.96%
|
0.05
+5.88%
|
0.05
|
| Cash Cash Equivalents And Short Term Investments |
|
12.46
+388.02%
|
2.55
+6129.27%
|
0.04
+13.89%
|
0.04
|
| Cash And Cash Equivalents |
|
1.31
-48.86%
|
2.55
+63750.00%
|
0.00
-88.89%
|
0.04
|
| Other Short Term Investments |
|
11.16
|
0.00
-100.00%
|
0.04
|
0.00
|
| Other Current Assets |
|
0.40
+300.00%
|
0.10
+661.54%
|
0.01
-13.33%
|
0.01
|
| Total Non Current Assets |
|
8.58
+196.37%
|
2.89
+473.07%
|
0.51
+2.02%
|
0.49
|
| Net PPE |
|
0.01
+20.00%
|
0.01
-16.67%
|
0.01
-25.00%
|
0.02
|
| Goodwill And Other Intangible Assets |
|
2.55
-11.69%
|
2.88
|
0.00
|
—
|
| Non Current Deferred Assets |
|
—
|
0.00
-100.00%
|
0.49
+2.92%
|
0.48
|
| Non Current Prepaid Assets |
|
6.02
|
0.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
0.44
+69.73%
|
0.26
-65.20%
|
0.75
-48.13%
|
1.45
|
| Current Liabilities |
|
0.44
+69.73%
|
0.26
-48.01%
|
0.50
-58.10%
|
1.20
|
| Payables And Accrued Expenses |
|
0.29
+36.11%
|
0.22
+36.71%
|
0.16
+12.06%
|
0.14
|
| Current Accrued Expenses |
|
0.29
+36.11%
|
0.22
+36.71%
|
0.16
+12.06%
|
0.14
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.15
+231.11%
|
0.04
+15.38%
|
0.04
+5.41%
|
0.04
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.20
-67.85%
|
0.62
|
| Current Debt |
|
—
|
—
|
0.20
-67.85%
|
0.62
|
| Other Current Borrowings |
|
—
|
—
|
0.20
-67.85%
|
0.62
|
| Other Current Liabilities |
|
—
|
—
|
0.10
-73.62%
|
0.40
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
-100.00%
|
0.25
+0.00%
|
0.25
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
0.25
+0.00%
|
0.25
|
| Stockholders Equity |
|
20.99
+297.16%
|
5.29
+2867.54%
|
-0.19
+78.78%
|
-0.90
|
| Common Stock Equity |
|
20.99
+297.16%
|
5.29
+2867.54%
|
-0.19
+78.78%
|
-0.90
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
0.98
+34954.61%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Ordinary Shares Number |
|
0.98
+34954.61%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Additional Paid In Capital |
|
29.39
+183.95%
|
10.35
+193.59%
|
3.53
+74.47%
|
2.02
|
| Retained Earnings |
|
-8.40
-65.83%
|
-5.07
-43.88%
|
-3.52
-20.54%
|
-2.92
|
| Total Equity Gross Minority Interest |
|
20.99
+297.16%
|
5.29
+2867.54%
|
-0.19
+78.78%
|
-0.90
|
| Total Capitalization |
|
20.99
+297.16%
|
5.29
+2867.54%
|
-0.19
+78.78%
|
-0.90
|
| Working Capital |
|
12.42
+419.11%
|
2.39
+633.93%
|
-0.45
+60.94%
|
-1.15
|
| Invested Capital |
|
20.99
+297.16%
|
5.29
+58633.33%
|
0.01
+103.24%
|
-0.28
|
| Total Debt |
|
—
|
—
|
0.20
-67.85%
|
0.62
|
| Net Debt |
|
—
|
—
|
0.20
-66.55%
|
0.59
|
| Net Tangible Assets |
|
18.45
+667.99%
|
2.40
+1357.59%
|
-0.19
+78.78%
|
-0.90
|
| Tangible Book Value |
|
18.45
+667.99%
|
2.40
+1357.59%
|
-0.19
+78.78%
|
-0.90
|
| Other Equity Interest |
|
—
|
—
|
-0.20
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.53
-294.77%
|
-1.15
-113.59%
|
-0.54
+52.56%
|
-1.13
|
| Cash Flow From Continuing Operating Activities |
|
-4.53
-294.77%
|
-1.15
-113.59%
|
-0.54
+52.56%
|
-1.13
|
| Net Income From Continuing Operations |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Depreciation Amortization Depletion |
|
0.34
+189.83%
|
0.12
+2850.00%
|
0.00
-20.00%
|
0.01
|
| Depreciation |
|
—
|
0.12
+2850.00%
|
0.00
-20.00%
|
0.01
|
| Depreciation And Amortization |
|
0.34
+189.83%
|
0.12
+2850.00%
|
0.00
-20.00%
|
0.01
|
| Other Non Cash Items |
|
2.46
+7825.81%
|
0.03
-86.40%
|
0.23
+976.92%
|
-0.03
|
| Stock Based Compensation |
|
1.31
+2468.63%
|
0.05
-49.00%
|
0.10
-23.08%
|
0.13
|
| Operating Gains Losses |
|
-5.14
-2537.91%
|
0.21
+172.01%
|
-0.29
-148.31%
|
-0.12
|
| Gain Loss On Investment Securities |
|
-5.14
-2537.91%
|
0.21
+172.01%
|
-0.29
-148.31%
|
-0.12
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
-100.00%
|
0.01
-52.94%
|
0.02
|
0.00
|
| Change In Working Capital |
|
-0.16
-652.38%
|
-0.02
-400.00%
|
0.01
+102.03%
|
-0.34
|
| Change In Payables And Accrued Expense |
|
0.04
-39.66%
|
0.06
+241.18%
|
0.02
+213.33%
|
-0.01
|
| Change In Accrued Expense |
|
0.04
-39.66%
|
0.06
+241.18%
|
0.02
+213.33%
|
-0.01
|
| Change In Other Working Capital |
|
0.10
+1633.33%
|
0.01
+150.00%
|
-0.01
+96.42%
|
-0.34
|
| Change In Other Current Assets |
|
-0.30
-249.41%
|
-0.09
-4350.00%
|
0.00
-66.67%
|
0.01
|
| Investing Cash Flow |
|
-16.53
-57113.79%
|
0.03
|
0.00
+100.00%
|
-0.00
|
| Cash Flow From Continuing Investing Activities |
|
-16.53
-57113.79%
|
0.03
|
0.00
+100.00%
|
-0.00
|
| Net PPE Purchase And Sale |
|
-0.01
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Purchase Of PPE |
|
-0.01
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Capital Expenditure |
|
-0.01
|
—
|
—
|
-0.00
|
| Net Investment Purchase And Sale |
|
-16.53
-57089.66%
|
0.03
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-16.53
|
0.00
|
0.00
|
—
|
| Sale Of Investment |
|
0.00
-100.00%
|
0.03
|
0.00
|
0.00
|
| Financing Cash Flow |
|
19.81
+440.19%
|
3.67
+626.34%
|
0.51
-22.07%
|
0.65
|
| Cash Flow From Continuing Financing Activities |
|
19.81
+440.19%
|
3.67
+626.34%
|
0.51
-22.07%
|
0.65
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.01
-102.41%
|
0.25
-61.57%
|
0.65
|
| Issuance Of Debt |
|
0.00
-100.00%
|
0.31
+24.50%
|
0.25
-61.57%
|
0.65
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.32
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
0.31
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-0.32
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-0.01
|
0.00
|
0.00
|
| Short Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
0.25
-61.57%
|
0.65
|
| Net Short Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
0.25
-61.57%
|
0.65
|
| Net Common Stock Issuance |
|
19.81
+439.30%
|
3.67
+1335.16%
|
0.26
|
0.00
|
| Changes In Cash |
|
-1.25
-148.94%
|
2.55
+8068.75%
|
-0.03
+93.43%
|
-0.49
|
| Beginning Cash Position |
|
2.55
+63750.00%
|
0.00
-88.89%
|
0.04
-93.12%
|
0.52
|
| End Cash Position |
|
1.31
-48.86%
|
2.55
+63750.00%
|
0.00
-88.89%
|
0.04
|
| Free Cash Flow |
|
-4.54
-295.38%
|
-1.15
-113.59%
|
-0.54
+52.69%
|
-1.14
|
| Common Stock Issuance |
|
19.81
+439.30%
|
3.67
+1335.16%
|
0.26
|
0.00
|
| Issuance Of Capital Stock |
|
19.81
+439.30%
|
3.67
+1335.16%
|
0.26
|
0.00
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|